Traitement Anémie aplastique en République de Corée — recevez 3 correspondances personnalisées de cliniques

South Korean medical centers treat severe aplastic anemia with hematopoietic stem cell transplantation (HSCT) and intensive immunosuppressive therapy (IST). Younger patients often receive allogeneic bone marrow transplantation from matched siblings. Older patients or those without donors utilize drug regimens combining antithymocyte globulin with cyclosporine and eltrombopag.

• Matched donor HSCT: Curative first-line treatment for patients under age 50 with HLA-matched donors.
• Immunosuppressive therapy: Combination of antithymocyte globulin and cyclosporine for patients without donors.
• Triple drug therapy: Addition of eltrombopag to standard immunosuppression helps boost blood cell production.
• Partial match options: Haploidentical transplantation allows family members to serve as donors for severe cases.

Bookimed Expert Insight: Korea's infrastructure is uniquely suited for complex hematology due to its high-volume digitalized centers. Asan Medical Center alone performs over 65,000 operations annually and maintains a 90% success rate in organ transplants. This volume translates to highly refined protocols for preventing infections during the vulnerable weeks following bone marrow replacement.

Patient Consensus: Patients note it's important to start HLA testing immediately because Korea's donor registry is highly efficient. Many emphasize the need to arrange long-term housing near the hospital for the 3-to-6 month recovery period.

South Korea manages the horse ATG shortage by using rabbit-derived anti-thymocyte globulin as the primary immunosuppressive therapy. Hospitals combine rabbit ATG with cyclosporine and methylprednisolone. Major centers also integrate eltrombopag to improve blood cell counts. Bone marrow transplantation serves as the definitive curative alternative.

• Standard protocol: Thymoglobulin (rabbit ATG) replaced horse-derived options in first-line clinical guidelines.
• Response monitoring: Korean data shows rabbit ATG requires long-term observation exceeding one year.
• Add-on therapy: Eltrombopag is increasingly used to boost hematologic response in severe cases.
• Transplant strategy: Allogenic bone marrow transplantation provides a curative path if immunotherapy fails.
• Conditioning benefits: Rabbit ATG may offer better protection against Graft-versus-Host Disease during transplants.

Bookimed Expert Insight: Korea's heavy investment in digital infrastructure at centers like Seoul National University Bundang Hospital ensures precise long-term monitoring. Since over 50% of Korean patients require more than one year to respond to rabbit ATG, these digital tracking systems are vital for adjusting therapy. Hospitals like Asan Medical Center, performing over 65,000 surgeries annually, often transition patients to transplant quickly if immunosuppression doesn't show early promise.

Patient Consensus: Patients note it is important to prepare for a longer medical journey than expected. Practical focus often shifts toward finding specialized hematologists in Seoul who can manage the extended follow-up care required for rabbit-based regimens.

Korean medical centers report a 95% 5-year overall survival rate for severe aplastic anemia using bone marrow transplantation. This success rate applies to patients receiving tissue from HLA-identical sibling donors. These outcomes exceed survival rates of 70% typically observed with immunosuppressive therapy protocols.

• Donor type: Sibling donor transplants achieve 95% survival after a 42-month follow-up.
• Unrelated donors: Transplants from unrelated donors show 8-year survival rates of 75% or higher.
• Age factor: Patients under 50 demonstrate 85% survival compared to 26.7% for older groups.
• Conditioning protocols: Specialized regimens using fludarabine help improve long-term outcomes for unrelated transplants.

Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. This high volume allows for ultra-specialization in complex donor matching and conditioning. Our data shows that centers with these certifications maintain consistency in 5-year survival reporting.

Patient Consensus: Visitors suggest that the administrative speed in Seoul helps reduce wait times for transplant. Many note that clear communication about donor compatibility from the start reduces stress during recovery.

Korean hospitals are highly prepared for international aplastic anemia patients. Major centers like Samsung Medical Center provide dedicated international departments with coordinators and translators. These facilities combine high transplantation volumes with Joint Commission International accreditation to ensure safety for foreign nationals seeking complex hematologic care.

• Specialized centers: Asan Medical Center performs approximately 50% of the country's transplant cases.
• Advanced diagnostics: Facilities use cytogenetic screening and bone marrow biopsy for precise staging.
• Language support: International desks at clinics like Severance Hospital offer full English-speaking coordination.
• Administrative assistance: Dedicated teams manage medical visas and travel logistics for foreign patients.

Bookimed Expert Insight: The data shows a powerful link between high patient volume and successful outcomes in Seoul. Asan Medical Center manages over 10,000 daily outpatients and handles nearly half of the nation's transplants. This massive clinical experience often leads to improved protocols and lower rejection rates for complex aplastic anemia cases.

Patient Consensus: Patients highlight that using hospital international desks helps prevent most logistical issues. They also recommend preparing medical record translations early to avoid delays in starting treatment after arrival.

International patients should plan for a 90-day stay in South Korea for a bone marrow transplant. This timeframe covers a 7-day diagnostic phase and 3 to 6 weeks of sterile hospitalization. Patients must remain near the hospital for 60 days of post-discharge monitoring to manage recovery.

• Diagnostic phase: Initial tests and donor matching require approximately 7 days before conditioning begins.
• Hospitalization period: Patients spend 21 to 42 days in specialized sterile isolation rooms.
• Monitoring phase: Daily or weekly follow-up visits continue for 60 days after hospital discharge.
• Total duration: Most clinical teams recommend a minimum stay of 3 full months.

Bookimed Expert Insight: While major centers like Asan Medical Center and Samsung Medical Center serve over 2,000,000 patients yearly, their high volume means isolation beds are tightly scheduled. If you miss your conditioning window, you might wait weeks for the next available sterile bed. Always confirm your bed reservation before booking flights, as these facilities maintain nearly 100% occupancy for transplant units.

Patient Consensus: Patients note it is vital to secure housing within 15 minutes of the hospital because post-discharge fatigue makes even short trips difficult. They also suggest planning for a 4 to 6-month stay to account for the slow recovery of the immune system.

Bone marrow transplants for severe aplastic anaemia in South Korea show a 95% five-year survival rate for patients with matched sibling donors. Centres such as Samsung Medical Center and Severance Hospital use modern haploidentical techniques. These methods achieve success rates reaching 90% even without perfectly matched donors.

• Sibling donors: Matched sibling transplants report an approximate 95% five-year overall survival rate.
• Unrelated donors: Survival rates for transplants from unrelated donors typically exceed 75% over eight years.
• Haploidentical success: Modern half-matched transplant techniques report success rates around 90% for difficult cases.
• Age impact: Patients under 50 see better outcomes, with survival rates averaging roughly 85%.
• Accredited facilities: Major hubs like SNUH and Asan Medical Center hold KOIHA and ISO certifications.

Bookimed Expert Insight: South Korea's transplant landscape is defined by digital integration. Centres like Seoul National University Bundang Hospital use the BESTcare system to reduce medical errors. This digital infrastructure supports high-volume transplant units at Asan Medical Center. Asan handles 180,000+ patients annually and reports organ transplant success rates from 90%.

Patient Consensus: Patients highlight that results depend heavily on finding a matched sibling donor. They advise checking specific survival data for their exact age group and donor type in Korea.

Seoul St. Mary's Hospital and Asan Medical Center lead South Korea in treating aplastic anaemia. These centres provide haematology services and stem cell transplantation. Other specialist facilities include Samsung Medical Center and Seoul National University Hospital. Most are JCI-accredited and hold KOIHA certification.

• Seoul St. Mary's: Known for the Catholic Hematology Hospital and bone marrow failure expertise.
• Asan Medical Center: Features a JCI-accredited unit performing 60,000+ annual operations across specialties.
• Samsung Medical Center: Holds Newsweek recognition and provides oncology and haematology care.
• SNUH: Operates as a leading state facility with digitised electronic health records.

Bookimed Expert Insight: Samsung Medical Center serves over 2 million patients annually. The Newsweek World's Best Hospitals list includes them for their complex case capacity. Large centres like this or Asan Medical Center offer integrated diagnostic methods. This includes cytogenetic bone marrow analysis and genetic screening within one facility.

Patient Consensus: Patients note that major tertiary centres in Seoul offer better access to beds. This includes bone marrow transplant beds and more donor options. They suggest confirmed English-speaking coordination is essential for managing intensive follow-up care.

South Korea hosts leading specialists for aplastic anaemia, particularly in Seoul-based tertiary centres. Experts such as Prof. Lee Jong-wook at Seoul St. Mary's Hospital and Dr Seung-ah Yahng provide specialised care. These specialists focus on haematopoietic stem cell transplantation and managing bone marrow failure.

• Specialist expertise: Haematologists in Korea often lead national research societies for bone marrow failure.
• Transplant centres: Major hospitals like Samsung Medical Center perform complex allogeneic bone marrow transplants.
• Quality standards: Key facilities hold JCI and KOIHA accreditations to meet strict international safety benchmarks.
• Diagnostics: Clinics provide comprehensive genetic screening and cytogenetic studies of the bone marrow.

Bookimed Expert Insight: Prof. Lee Jong-wook and others are highly sought after. Facilities like Samsung Medical Center and SNUH use digitalised records and telemedicine. This helps Australian patients manage long-term haematology follow-ups and record transfers after returning home.

Patient Consensus: Patients note that care in South Korea is hospital-based. It is essential to bring complete biopsy reports and arrange interpreters before arriving in Seoul.

South Korean medical centres treat refractory or relapsing aplastic anaemia using allogeneic haematopoietic stem cell transplantation (HSCT) and specialised pharmacological agents. Specialists prioritise unrelated or haploidentical transplants within six months of initial treatment failure. JCI-accredited hospitals in Seoul add eltrombopag to standard salvage protocols to improve patient outcomes.

• Allogeneic transplantation: Primary salvage therapy for patients failing immunosuppression using matched or unrelated donors.
• Haploidentical transplant: Provides a half-matched donor option from family members when no match exists.
• Pharmacological therapy: Eltrombopag (thrombopoietin receptor agonist) is combined with second-line immunosuppressive drugs.
• Clinical protocols: Korean guidelines recommend rapid intervention with specific anti-thymocyte globulin (ATG) regimens.

Bookimed Expert Insight: Many countries focus solely on matched donors. However, South Korean centres like Seoul National University Hospital specialise in haploidentical transplants. These facilities serve over 10,000 patients daily and use the BESTcare digital system. This high volume allows doctors to perfect mismatched donor protocols. These procedures are often less available in Australia.

Patient Consensus: Patients often highlight the speed of diagnosis in South Korea. This process involves bone marrow biopsies and genetic screening. They note that digital health records at major Seoul hospitals help manage complex transplant recovery.

Patients can usually start a stem cell transplant within 1 week of arriving in the Republic of Korea. Specialists at centres like Samsung Medical Center complete diagnostic tests and donor matching in about 7 days. Most patients stay 3 months for monitoring.

• Diagnostic phase: Experts complete marrow biopsies and HLA typing within 7 days.
• Hospital stay: Patients spend 21 to 42 days in specialised sterile isolation rooms.
• Engraftment timing: New stem cells usually start producing blood cells within 11 to 16 days.
• Total duration: Expect a minimum 3-month stay for essential post-transplant monitoring.

Bookimed Expert Insight: Samsung Medical Center and Asan Medical Center handle massive patient volumes, serving over 180,000 people annually. This high throughput allows these Seoul-based facilities to offer fast-tracked HLA testing. Their digitalised BESTcare systems further reduce administrative delays during donor registry searches.

Patient Consensus: Patients note that donor source strongly affects wait times in South Korea. They suggest starting HLA typing early to avoid delays if a family match isn't available.